Author:
Lankenau-Vela D,De la Garza-Salazar F,Colunga-Pedraza P,Jaime-Villalón D
Abstract
Epstein-Barr virus [EBV] is a virus that infects almost all humans worldwide. After the acute phase of the infection, it stays in a latent form in B lymphocytes. EBV reactivation tends to occur in immunosuppressed patients. EBV reactivation may involve the gastrointestinal tract ; it has been associated mainly with colitis, but hemorrhagic enteritis has been poorly reported. Treatment usually includes antivirals. However, our patient did not respond to conventional treatment, so interferon alpha-2a was given as a salvage treatment. To our knowledge, this is the first reported case of hemorrhagic enteritis associated to EBV reactivation treated successfully with interferon alpha-2a.
Reference12 articles.
1. BUSSCHAERT J., VAN DE BRUAENE C., VAN CAILLIE M., VAN HOOTEGEM P. A not-so-innocent kiss. Acta gastro-enterologica Belgica.,2019,82(4) : 552.
2. KERR J.R. Epstein-Barr virus (EBV) reactivation and therapeutic inhibitors. J. Clin. Pathol., 2019 : jclinpath-2019-205822.
3. LI H., LIU S., HU J., LUO X., LI N., BODE A.M., et al. Epstein-Barr virus lytic reactivation regulation and its pathogenic role in carcinogenesis. Int. J. Biol. Sci., 2016, 12(11) : 1309.
4. CIRELLI R., TYRING S.K. Major therapeutic uses of interferons. Clin. Immunother., 1995, 3(1) : 27-87.
5. SARWARI N.M., KHOURY J.D., HERNANDEZ C.M.R. Chronic Epstein Barr virus infection leading to classical Hodgkin lymphoma. BMC hema-tology, 2016, 16(1) : 19.